vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.
FrontView REIT, Inc. is the larger business by last-quarter revenue ($16.5M vs $13.8M, roughly 1.2× Gossamer Bio, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -342.3%, a 317.4% gap on every dollar of revenue.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
FVR vs GOSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $13.8M |
| Net Profit | $-4.1M | $-47.2M |
| Gross Margin | — | — |
| Operating Margin | — | -333.6% |
| Net Margin | -24.9% | -342.3% |
| Revenue YoY | — | 47.1% |
| Net Profit YoY | — | -43.0% |
| EPS (diluted) | $-0.19 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | $13.8M | ||
| Q3 25 | $16.8M | $13.3M | ||
| Q2 25 | $17.6M | — | ||
| Q1 25 | $16.2M | — | ||
| Q3 24 | $14.5M | — | ||
| Q2 24 | — | $95.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 |
| Q4 25 | $-4.1M | $-47.2M | ||
| Q3 25 | $4.0M | $-48.2M | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-833.0K | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | — | $49.2M | ||
| Q1 24 | — | $-41.9M | ||
| Q3 23 | — | $-40.0M |
| Q4 25 | — | -333.6% | ||
| Q3 25 | — | -369.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | -24.9% | -342.3% | ||
| Q3 25 | 23.9% | -362.7% | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -5.1% | — | ||
| Q3 24 | -16.7% | — | ||
| Q2 24 | — | 51.4% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | $-0.19 | $-0.21 | ||
| Q3 25 | $0.19 | $-0.21 | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.06 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $0.22 | ||
| Q1 24 | — | $-0.19 | ||
| Q3 23 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $136.9M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $-122.8M |
| Total Assets | $854.4M | $172.2M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $136.9M | ||
| Q3 25 | $19.6M | $180.2M | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $3.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $354.5M | ||
| Q1 24 | — | $244.4M | ||
| Q3 23 | — | $328.9M |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | $391.2M | $-122.8M | ||
| Q3 25 | $385.2M | $-82.3M | ||
| Q2 25 | $369.9M | — | ||
| Q1 25 | $324.7M | — | ||
| Q3 24 | $1.0K | — | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | — | $26.7M | ||
| Q3 23 | — | $104.6M |
| Q4 25 | $854.4M | $172.2M | ||
| Q3 25 | $846.8M | $208.8M | ||
| Q2 25 | $856.5M | — | ||
| Q1 25 | $860.8M | — | ||
| Q3 24 | $1.0K | — | ||
| Q2 24 | — | $373.4M | ||
| Q1 24 | — | $259.4M | ||
| Q3 23 | — | $347.9M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $-48.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | $-48.3M | ||
| Q3 25 | $8.3M | $-36.2M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $8.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $116.3M | ||
| Q1 24 | — | $-52.3M | ||
| Q3 23 | — | $-34.5M |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.36× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
